Onxeo has recently received the 10th unanimous recommendation from the Data Safety Monitoring Board to continue with the Phase 3 study (coined ReLive) of Livatag®.
Livatag® is designed for use in patients who have advanced hepatocellular carcinoma after they have failure or intolerance to sorafenib, and subjects of the ReLive study are still undergoing treatment.
Hepatocellular carcinoma is a rare form of primary liver cancer whose treatments currently revolve around radiation, chemotherapy, and surgery. To learn more about hepatocellular carcinoma, click here.
This recommendation is extremely encouraging for both Onxeo and Livatag®, as it solidifies that the drug has an acceptable tolerance profile for both safety and side effects reasons.
CEO of Onxeo, Judith Greciet said,
“This product candidate represents a potential new and innovative therapeutic option for patients suffering from this orphan and resistant cancer, and could become a potentially impactful catalyst for the Company.”
In addition to this recommendation, Livatag® has also recently received a Notice of Allowance from the U.S. Patent and Trademark Office, which would cover the specific route of administration for Livatag®. This new patent greatly enhances the value of the drug, as well as giving it the opportunity to emerge in the United States marketplace.
There are so many exciting new updates from the world of Livatag, and even before the completion of the Phase 3 clinical trial! Each one brings new hope and is a step in the right direction for bringing treatment to even the most difficult of cancer cases.
If you want to learn more about Livatag® before the results of the latest ReLive study come out, click here!
